These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

385 related items for PubMed ID: 29858843

  • 1. The effect of antidiabetic medications on non-alcoholic fatty liver disease (NAFLD).
    Iogna Prat L, Tsochatzis EA.
    Hormones (Athens); 2018 Jun; 17(2):219-229. PubMed ID: 29858843
    [Abstract] [Full Text] [Related]

  • 2. Diabetes drugs for nonalcoholic fatty liver disease: a systematic review.
    Blazina I, Selph S.
    Syst Rev; 2019 Nov 29; 8(1):295. PubMed ID: 31783920
    [Abstract] [Full Text] [Related]

  • 3. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
    Athyros VG, Alexandrides TK, Bilianou H, Cholongitas E, Doumas M, Ganotakis ES, Goudevenos J, Elisaf MS, Germanidis G, Giouleme O, Karagiannis A, Karvounis C, Katsiki N, Kotsis V, Kountouras J, Liberopoulos E, Pitsavos C, Polyzos S, Rallidis LS, Richter D, Tsapas AG, Tselepis AD, Tsioufis K, Tziomalos K, Tzotzas T, Vasiliadis TG, Vlachopoulos C, Mikhailidis DP, Mantzoros C.
    Metabolism; 2017 Jun 29; 71():17-32. PubMed ID: 28521870
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials.
    Mantovani A, Byrne CD, Scorletti E, Mantzoros CS, Targher G.
    Diabetes Metab; 2020 Nov 29; 46(6):427-441. PubMed ID: 31923578
    [Abstract] [Full Text] [Related]

  • 5. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.
    Athyros VG, Polyzos SA, Kountouras J, Katsiki N, Anagnostis P, Doumas M, Mantzoros CS.
    Curr Vasc Pharmacol; 2020 Nov 29; 18(2):172-181. PubMed ID: 30961499
    [Abstract] [Full Text] [Related]

  • 6. Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review.
    Shyangdan D, Clar C, Ghouri N, Henderson R, Gurung T, Preiss D, Sattar N, Fraser A, Waugh N.
    Health Technol Assess; 2011 Nov 29; 15(38):1-110. PubMed ID: 22059955
    [Abstract] [Full Text] [Related]

  • 7. NASH Therapy: omega 3 supplementation, vitamin E, insulin sensitizers and statin drugs.
    Caldwell S.
    Clin Mol Hepatol; 2017 Jun 29; 23(2):103-108. PubMed ID: 28494529
    [Abstract] [Full Text] [Related]

  • 8. What Does the Future Hold for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis?
    Doumas M, Imprialos K, Stavropoulos K, Athyros VG.
    Curr Vasc Pharmacol; 2019 Jun 29; 17(5):425-428. PubMed ID: 31418344
    [Abstract] [Full Text] [Related]

  • 9. Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!
    Ranjbar G, Mikhailidis DP, Sahebkar A.
    Metabolism; 2019 Dec 29; 101():154001. PubMed ID: 31672448
    [Abstract] [Full Text] [Related]

  • 10. Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions.
    Cusi K.
    Diabetologia; 2016 Jun 29; 59(6):1112-20. PubMed ID: 27101131
    [Abstract] [Full Text] [Related]

  • 11. The role of anti-diabetic drugs in NAFLD. Have we found the Holy Grail? A narrative review.
    Zachou M, Flevari P, Nasiri-Ansari N, Varytimiadis C, Kalaitzakis E, Kassi E, Androutsakos T.
    Eur J Clin Pharmacol; 2024 Jan 29; 80(1):127-150. PubMed ID: 37938366
    [Abstract] [Full Text] [Related]

  • 12. Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease.
    Budd J, Cusi K.
    Curr Diab Rep; 2020 Oct 05; 20(11):59. PubMed ID: 33015726
    [Abstract] [Full Text] [Related]

  • 13. Liraglutide With Metformin Therapy Ameliorates Hepatic Steatosis and Liver Injury in a Mouse Model of Non-alcoholic Steatohepatitis.
    Chiu HY, Tsai SC, Tsai FJ, Lo YH, Cheng CC, Liu TY, Jhan SR, Yang JS, Chiu YJ.
    In Vivo; 2023 Oct 05; 37(3):1037-1046. PubMed ID: 37103096
    [Abstract] [Full Text] [Related]

  • 14. Pharmacological management of nonalcoholic fatty liver disease.
    Barb D, Portillo-Sanchez P, Cusi K.
    Metabolism; 2016 Aug 05; 65(8):1183-95. PubMed ID: 27301803
    [Abstract] [Full Text] [Related]

  • 15. Liraglutide Decreases Hepatic Inflammation and Injury in Advanced Lean Non-Alcoholic Steatohepatitis.
    Ipsen DH, Rolin B, Rakipovski G, Skovsted GF, Madsen A, Kolstrup S, Schou-Pedersen AM, Skat-Rørdam J, Lykkesfeldt J, Tveden-Nyborg P.
    Basic Clin Pharmacol Toxicol; 2018 Dec 05; 123(6):704-713. PubMed ID: 29953740
    [Abstract] [Full Text] [Related]

  • 16. Effect of liraglutide therapy on serum fetuin A in patients with type 2 diabetes and non-alcoholic fatty liver disease.
    Zhang LY, Qu XN, Sun ZY, Zhang Y.
    Clin Res Hepatol Gastroenterol; 2020 Oct 05; 44(5):674-680. PubMed ID: 32113823
    [Abstract] [Full Text] [Related]

  • 17. Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis.
    Mahjoubin-Tehran M, De Vincentis A, Mikhailidis DP, Atkin SL, Mantzoros CS, Jamialahmadi T, Sahebkar A.
    Mol Metab; 2021 Aug 05; 50():101049. PubMed ID: 32673798
    [Abstract] [Full Text] [Related]

  • 18. SGLT-2 Inhibitors: Are They a Promising Treatment Option in T2DM Patients with NAFLD?
    Patoulias D.
    Acta Medica (Hradec Kralove); 2017 Aug 05; 60(4):167-170. PubMed ID: 29716685
    [Abstract] [Full Text] [Related]

  • 19. Effects of Oral Antidiabetic Drugs on Changes in the Liver-to-Spleen Ratio on Computed Tomography and Inflammatory Biomarkers in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease.
    Yabiku K, Mutoh A, Miyagi K, Takasu N.
    Clin Ther; 2017 Mar 05; 39(3):558-566. PubMed ID: 28185715
    [Abstract] [Full Text] [Related]

  • 20. Liraglutide protects against inflammatory stress in non-alcoholic fatty liver by modulating Kupffer cells M2 polarization via cAMP-PKA-STAT3 signaling pathway.
    Li Z, Feng PP, Zhao ZB, Zhu W, Gong JP, Du HM.
    Biochem Biophys Res Commun; 2019 Feb 26; 510(1):20-26. PubMed ID: 30683312
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.